Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc. is positioned for substantial revenue growth, particularly with the introduction of Giapreza, which addresses the critical unmet need in septic and distributive shock management, supported by updated treatment guidelines and a growing patient population. The recent launch of Xacduro has shown a remarkable sales trajectory, with forecasts indicating a leap from $2.0 million in 2023 to $95.3 million by 3Q25, reflecting the product's strong market acceptance and significant potential in the critical care sector. Additionally, the company's overall product sales have demonstrated impressive year-over-year growth rates, fostering a solid foundation for Innoviva’s expanding commercial momentum and profitability.

Bears say

Innoviva Inc faces considerable risks that may adversely impact its financial performance, including substantial mortality rates associated with MRSA infections, which complicates the treatment landscape for its critical care assets. Additionally, there are multiple uncertainties surrounding the successful commercialization of its marketed products and the timely launch of new treatments like ZEVTERA and zoliflodacin, all of which could hinder revenue growth. Furthermore, potential declines in royalty revenue from respiratory-focused products due to generic erosion, alongside macroeconomic factors and partnership risks, introduce further challenges to Innoviva's financial stability.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.